Tumor response assessment to chemotherapy by MRI in Carcinoma Breast.

Assessment of Diffusion-Weighted MRI in Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082033

Enrollment

Registered

2025-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast

Interventions

Intervention1: Assessment of Diffusion-Weighted MRI in Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients: 1.Detailed history of all study participants will be

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female patients aged 18-70 years 2.Diagnosed with locally advanced breast cancer 3.Planned to receive NACT

Exclusion criteria

Exclusion criteria: 1.Contraindications to MRI 2.Previous treatment for breast cancer

Design outcomes

Primary

Measure	Time frame
Evaluate the predictive value of DW-MRI in assessing response to NACT in breast cancerTimepoint: At 6 months	—

Secondary

Measure	Time frame
To corelate pathological response with ADC values of MRITimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr A Kesava Ramgopal

AIIMS Mangalagiri

Kesav.rt@aiimsmangalagiri.edu.in9491331850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026